- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer (SCLC) Patients (LAGOON Trial)
This study looks at new ways to treat small cell lung cancer that has come back. It compares a drug called lurbinectedin, alone or with irinotecan, against standard treatments to see which helps patients live longer and clearer of cancer.
For: Small Cell Lung Cancer (SCLC)Poland · France · Germany - RecruitingPHASE2, PHASE3
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This study is looking at a new medicine called R-DXd for certain types of advanced ovarian, primary peritoneal, or fallopian tube cancer that haven't responded well to platinum chemotherapy. It aims to find out if R-DXd is safe and effective.
For: Solid CancerUnited States · Australia · Brazil - RecruitingPHASE3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
This study is looking at a new medicine called sacituzumab govitecan (SG) for people with a type of lung cancer called extensive stage small cell lung cancer (ES-SCLC) that has been treated before. We want to see if SG works better than standard treatments to help people live longer.
For: Extensive Stage Small Cell Lung Cancer (ES-SCLC)United States · Argentina · Australia - Active not recruitingPHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
This study compares a new treatment called Sacituzumab Tirumotecan with standard care for recurrent or metastatic cervical cancer. It aims to see if the new treatment improves how long people live when current treatments aren't enough.
For: Cervical CancerUnited States · Argentina · Australia - Active not recruitingPHASE1
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
This study is for adults with a type of lung cancer called small cell lung cancer that has spread. It checks how well a new medicine called BI 764532, given with standard chemotherapy, is tolerated. The main goal is to find the safest dose of BI 764532.
For: Small Cell Lung Carcinoma (SCLC)United States · France · Germany - RecruitingPHASE3
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
This study is testing a new medicine, Ris-Rez, for advanced small cell lung cancer that has come back. It aims to see if Ris-Rez works better than standard treatment (topotecan) to shrink tumours and help people live longer, while also checking its safety.
For: Neoplasms, LungArgentina · Australia · Brazil - Active not recruitingPHASE1
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
This study is looking at a new medicine called LY3295668 erbumine for children and young people aged 2 to 21 with a type of cancer called neuroblastoma. We want to find out if this medicine is safe when neuroblastoma has come back or not responded to other treatments.
For: NeuroblastomaUnited States · Australia · Belgium - Active not recruitingPHASE2
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
This study looks at a new drug, palbociclib, combined with standard chemotherapy for children, teenagers, and young adults with certain cancers that have come back or are hard to treat. It aims to find a safe dose and see how well it works.
For: Ewing Sarcoma · Solid Tumors · Rhabdoid TumorUnited States · Brazil · Canada - Active not recruitingPHASE3
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
This study is looking at a new treatment called Tarlatamab for advanced small cell lung cancer that has come back after earlier treatment. We want to see if Tarlatamab helps people live longer compared to standard chemotherapy.
For: Small Cell Lung Cancer (SCLC)United States · Argentina · Australia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
C5721002 _ A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
This study is testing a new drug (Tisotumab Vedotin) for cervical cancer that has come back or spread, and hasn't responded to previous treatments. It compares whether the new drug works better than standard chemotherapy to help people live longer.
For: Second- or Third-Line Recurrent or Metastatic Cervical CancerSweden · Czechia · Finland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, vs Investigator's Choice Chemotherapy in Women with Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This study is looking at a new medicine called farletuzumab ecteribulin for women with ovarian, primary peritoneal, or fallopian tube cancer that hasn't responded to previous platinum-based chemotherapy. Researchers want to see if this new drug shrinks tumours or stops them growing compared to standard treatments.
For: Platinum-resistant High-grade Serous Ovarian · Primary Peritoneal · or Fallopian Tube CancerBelgium · Italy · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma
This study looks at new ways to treat children with neuroblastoma that has come back or not responded to previous treatments. It combines standard chemotherapy drugs with a new medicine called bevacizumab to see if this helps shrink the cancer or stop it from growing.
For: NeuroblastomaBelgium · Spain · Netherlands - RecruitingPHASE3
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
This study is looking into a new drug, AZD5335, for women with advanced ovarian cancer that has become resistant to usual chemotherapy. It compares AZD5335 to existing treatments to see if it works better at controlling the cancer's growth.
For: Epithelial Ovarian CancerUnited States · Australia · Belgium - RecruitingPHASE3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
This study is testing a new medicine, Sofetabart Mipitecan, for certain ovarian, fallopian tube, and peritoneal cancers. It aims to see if it works better than current treatments and is safe, for people whose cancer either has or hasn't responded well to previous platinum-based treatments.
For: Ovarian Neoplasms · Fallopian Tube Neoplasms · Peritoneal NeoplasmsUnited States · Australia · Austria - RecruitingPHASE1, PHASE2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
This study is for children and young people with cancer that hasn't responded to usual treatments. It tests new medicines that target specific changes in cancer cells, aiming to find the right dose and see if they help. The goal is to find better ways to treat childhood cancer.
For: Pediatric CancerDenmark · France · Italy - RecruitingPHASE1, PHASE2
A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
This study looks for better ways to treat neuroblastoma in children and young people when it comes back. It tests new drug combinations to improve survival and quality of life for patients and to understand the disease better.
For: Relapsed NeuroblastomaAustralia · Austria · Belgium - RecruitingPHASE3
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
This study is looking at a new medicine called ifinatamab deruxtecan (I-DXd) for small cell lung cancer that has come back. It compares I-DXd to standard treatments to see if it works better and is safe.
For: Small Cell Lung CancerUnited States · Australia · Austria - Active not recruitingPHASE2
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
This study is looking at a new treatment called BNT327 for tiny-cell lung cancer. It combines BNT327 with chemotherapy to see how safe and effective it is for people whose cancer is widespread or has come back after other treatments.
For: Extensive-stage Small-cell Lung Cancer · Small-cell Lung CancerUnited States · Australia · South Korea - AuthorisedPhase I and Phase II (Integrated)- Other
BEACON 2: A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma
This study, BEACON 2, is looking for better ways to treat neuroblastoma, a type of cancer, in young people and adults when it has come back or not responded to previous treatments. It tests new combinations of existing medicines.
For: High risk relapsed neuroblastoma (relapsed or progressed after being defined as High Risk at any time following diagnosis or progressed/relapsed as high-risk neuroblastoma) · which is histologically proven as per International Neuroblastoma Staging System (INSS) definition.France · Austria · Germany